A national effort of historic proportions has been mounted to defeat cancer which has recently overtaken cardiovascular disease as the nation’s most deadly disease. Why this crusade has assumed such great proportion is perhaps inherent in cancer’s striking as harshly at human dignity as it does at life. And, very frequently, representing financial catastrophe for families in which it strikes. Medical research is approaching the problem from every possible orthodox and newly innovative direction. Special concentration is being urged in exploring areas of particular promise. Private research facilities, where unique cancer research opportunities exist, are being encouraged in their efforts. The Syracuse Cancer Research Institute represents one of these facilities.
At present SCRI is engaged in two major directions. The first is to sponsor joint clinical studies with cancer centers and universities for further clinical testing of hydrazine sulfate, the anticancer drug delevolped by the Institute, especially in cancers for which there are no effective treatments. One of these, for example, is the brain cancer glioblastoma multiforme, which characteristically has a very short prognosis time, no matter what the treatment. Both study and anecdotal results suggest that hydrazine sulfate may be effective in promoting long-term regression and survival in this cancer. Sponsorship of such proposed joint clinical studies can be very expensive, and the Institute invites individual participants to help sponsor these studies.
A second major activity of the Institute is enlargement of its Global Outreach Program. This program makes available to physicians and patients all over the world, at no expense to them, information and studies of hydrazine sulfate published in the medical literature. This is done by computer or by mail. The Institute will answer telephone calls from doctors or patients for specific, detailed information, also at no charge or fee. This program has been a huge success and its enlargement promises to be of aid to countless number of cancer patients, their families, friends and loved ones as well as to concerned physicians and caregivers.
A third program the Institute has embarked upon and will enlarge is its assistance to small animals—predominantly dogs and cats—who have developed cancer and to their owners. The Institute has received repeated reports from veterinarians and pet owners that cats and dogs with solid cancers have responded well to hydrazine sulfate, in many instances the treatment resulting in reported long-term, cancer-free survival or cure. Currently 30 percent of the Institute’s telephone calls or faxes—from all over the world—are veterinary sourced. This program will become a major mission of the Institute, since cancer strikes so many of these animals. The Institute has recently established the Elwood Fund to aid animals with cancer, provide information on hydrazine sulfate to veterinarians and pet owners and to help sponsor veterinary studies for animals confronted by various end-stage disease.
Dr. Joseph Gold
Founder and Director of SCRI
Dr. Gold received his A.B. at Cornell Univerity and his M.D. at SUNY, Upstate Medical University at Syracuse, New York. After completion of a U.S. Public Health Service Post-Doctoral Research Fellowship at the University of California School of Medicine at Berkeley, he was inducted into the Air Force as a Research Medical Officer. He was awarded a Presidential Citation for his work in the Mercury Astronaut Selection Program by President Dwight D. Eisenhower. After serving as Fellow, Research Assistant Professor and Assistant Professor in the Departments of Pharmacology and Pathology at SUNY Upstate Medical University, Dr. Gold established the Syracuse Cancer Research Institute in 1966, of which he is the current director. Dr. Gold is a member of the American Association for Cancer Research, the Onondaga County Medical Society, the Medical Society of the State of New York, and is a Diplomate of the National Board of Medical Examiners. He is the author of numerous articles in medical and scientific literature, and the holder of several U.S. and foreign patents. He is internationally recognized in the field of intermediary cancer metabolism. His work in the field of cancer chemotherapy and as the developer of Hydrazine Sulfate has been the subject of many national magazine articles and TV news stories. He has been named to Who's Who in America and Who's Who in the World.